COMPANY · NIPC 500207410

OM PHARMA S.A

This page shows the public contracts the company has signed, which bodies gave them, and who it competed against.

Portal BASE records €43,641,405.11 across 766 contracts.

Follow (RSS) · What is RSS?

Identification

Company nameOM PHARMA S.A
NIPC500207410

None of the registers we read (GLEIF, TED and contract documents) identifies this company; the name comes from Portal BASE contracts.

Contracted money

Sums of the contract prices on Portal BASE. A contract with several buyers or municipalities counts once in each row, so rows do not add up to the total.

Contracted value by yearBars with the value contracted in each year, from 2012 to 2023. The table below gives the same values.2012: €147,141.9620122013: €217,230.342014: €5,625,045.3820142015: €5,104,023.612016: €2,159,152.9820162017: €1,733,230.152018: €1,967,498.4220182019: €6,325,249.412020: €4,719,101.6520202021: €9,349,411.352022: €6,191,006.5520222023: €103,313.31€9,349,411.35
Contracted value by year
YearContractsContract value
20126€147,141.96
201320€217,230.34
201424€5,625,045.38
201547€5,104,023.61
201645€2,159,152.98
201757€1,733,230.15
201871€1,967,498.42
2019126€6,325,249.41
2020145€4,719,101.65
2021165€9,349,411.35
202259€6,191,006.55
20231€103,313.31
Contracted value by place of performance
NameContractsContract value
Coimbra23€8,790,946.95
Setúbal69€5,538,143.55
Lisboa79€4,936,876.36
Faro44€3,886,914.43
Santa Maria da Feira21€2,222,946.07
Barreiro30€1,701,890.97
Almada34€1,605,829.43
Évora12€1,395,674
Portalegre41€981,931.81
Vila Nova de Gaia43€834,859.80
Largest contracts
SubjectYearContract value
Medicamentos de consumo geral grupo 4 - sangue - C/ Base no CPA 2014/182015€4,094,676.76
Medicamentos do grupo 4 - sangue2014€3,744,030.91
MEDICAMENTOS DE CONSUMO GERAL (CP 2013/18, 48, 49, 50 E 51 - SPMS)2014€903,436.38
P259-2021-100 - Convite ao abrigo do(s) acordo(s)-quadro 2019/40, 2020/18 , 2021/6, 2019/55 , para aquisição de medicamentos para suprir necessidades na área da saúde.2022€874,579.50
P259-2021-036 - Aquisição de Medicamentos ao abrigo dos Acordos Quadro 2017/6, 2017/67, 2018/55, 2018/64, 2019/40, 2019/61, 2020/18, 2020/2, 2020/50 no âmbito da agregação centralizada 20212021€872,191.34

Who they competed with

In 1,903 contracts with a list of competitors, the company took part and was awarded 273 (14%).

Companies with the most procedures in common
CompanyProcedures in common
generis174
accord healthcare unipessoal, lda105
pfizer103
sandoz farmaceutica96
lab medinfar95
Overpharma-Produtos Médicos e Farmacêuticos, Lda87
labesfal, sa86
b.braun84
mylan84
farmoz80
unilfarma71
sanofi prod farmac.67
Bayer, S.A.54
hikma53
Laboratórios Normon, SA46
leo43
Merck, Sharp & Dohme, Lda.39
LOGIFARMA, LOGISTICA FARMACEUTICA, S.A.36
Novartis SA34
ucb pharma34
Fresenius Kabi Pharma Portugal,Lda33
Teva Pharma-Prod.Farmacêuticos32
bial31
roche farmaceutica31
Tecnifar-Indústria Técnica Farmacêutica, S.A.31
angelini30
Astrazeneca29
spcare29
Glaxosmithkline - Produtos Farmaceuticos Lda27
Amgen, Lda.26

The annual IMPIC file lists competitors for about 42% of contracts. Only these enter the counts, and the award share is measured on them.

Links read in contract documents

Contract documents give addresses and the names of representatives and partners, and Portal BASE and GLEIF give competitors and groups. This is what the records show; the same address or name can have simple explanations.

Links read in contract documents37 companies and 60 links. The list below gives the same content as text.Bayer, S.A. (NIPC 500043256)Bayer, S.A.Novartis SA (NIPC 500063524)Novartis SAsanofi prod fa… (NIPC 500134960)sanofi prod fa…Glaxosmithklin… (NIPC 500139962)Glaxosmithklin…pfizer (NIPC 500162166)pfizerMerck, Sharp &… (NIPC 500191360)Merck, Sharp &…NIPC 500207410 (NIPC 500207410)NIPC 500207410bial (NIPC 500220913)bialroche farmaceu… (NIPC 500233810)roche farmaceu…ucb pharma (NIPC 500291322)ucb pharmaunilfarma (NIPC 500293023)unilfarma+26 in the list below

Dotted: competed in the same procedure. Dotted: same procedure.

48 more links

Investigations that mention it

No published investigation mentions this company by NIPC.